Calculation of Average Cost Effectiveness Ratio in Hypertensive Patients Using Angiotensin-Converting Enzyme Inhibitor Combined with Calcium Channel Blocker in Inpatient Pharmacy Facility

Fendy Prasetyawan; Yuneka Saristiana; Faisal Akhmal Muslikh; Ratna Mildawati; Wahyu  Ariawan; Chandra Arifin; Abd Rofiq; Eka Amalia Putri; Ilhawa Zahra

doi:10.55927/metropolis.v1i1.68

Authors

Fendy Prasetyawan Universitas Kadiri
Yuneka Saristiana Universitas Kadiri
Faisal Akhmal Muslikh Institut Ilmu Kesehatan Bhakti Wiyata
Ratna Mildawati STIKes Ganesha Husada Kediri
Wahyu Ariawan STIKes Adila
Chandra Arifin Akademi Kesehatan Arga Husada
Abd Rofiq Akademi Kesehatan Arga Husada
Eka Amalia Putri STIKes Karya Putra Bangsa
Ilhawa Zahra Universitas Sari Mutiara

DOI:

https://doi.org/10.55927/metropolis.v1i1.68

Keywords:

Average Cost Effectiveness Ratio (ACER), Hypertensive, Angiotensin Converting Enzyme (ACE) Inhibitor, Calcium Channel Blocker (CCB)

Abstract

The study investigates the cost-effectiveness of Angiotensin-Converting Enzyme Inhibitor (ACEI) combined with Calcium Channel Blocker (CCB) therapy for hypertension management, revealing insights into its efficacy and economic implications. The therapy incurred a total cost of Rp. 1,485,500 with an effectiveness rate of 43%, resulting in an Average Cost Effectiveness Ratio (ACER) of Rp. 34,547 per unit of effectiveness. These findings highlight ACEI-CCB combination therapy as a viable option for blood pressure control and cardiovascular risk reduction, offering a balance between clinical efficacy and economic considerations. Despite study limitations, including retrospective data and single-site analysis, the results underscore the therapy's favorable cost-effectiveness and its potential to optimize hypertension management and resource allocation for improved patient care delivery.

References

Ademi, Z., Kim, H., Zomer, E., Reid, C. M., Hollingsworth, B., & Liew, D. (2013). Overview of pharmacoeconomic modelling methods. British Journal Of Clinical Pharmacology, 75(4), 944-950.

Andayani, T. (2016). The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients. Indonesian Journal of Pharmacy, 224-230.

D’Errico, C. C. (1998). Pharmacoeconomics Analysis In A Pediatric Population. The Annals Of Thoracic Surgery, 65(6), S52-S55.

Dahlöf, B. (2009). Management of cardiovascular risk with RAS inhibitor/CCB combination therapy. Journal Of Human Hypertension, 23(2), 77-85.

Dianati, S., Prasetyawan, F., Dewantara, A. A., & Prasetya, D. Y. (2022). Analisis Efektivitas Biaya Antihipertensi Oral Candesartan Dan Amlodipin Pada Pasien Hipertensi Rawat Inap Rs Bhayangkara Kediri. Java Health Jounal, 9(1).

Freund, D. A., & Dittus, R. S. (1992). Principles of pharmacoeconomic analysis of drug therapy. PharmacoEconomics, 1(1), 20-29.

Levin, H. M., & McEwan, P. J. (2001). Cost-effectiveness analysis: Methods and applications (Vol. 4). Sage.

McInnes, G. T. (2005). Lowering blood pressure for cardiovascular risk reduction. Journal of hypertension, 23, S3-S8.

Pongpanich, P., Pitakpaiboonkul, P., Takkavatakarn, K., Praditpornsilpa, K., Eiam-Ong, S., & Susantitaphong, P. (2018). The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. International urology and nephrology, 50, 2261-2278.

Restyana, A., Prasetyawan, F., Saristiana, Y., Dentika, N. A., & Jannah, N. N. (2022). Analisa Biaya Terapi Antibiotik Ceftriakson pada Pasien Infeksi Demam Tifoid Rawat Inap Rumah Sakit Tahun 2020. Jurnal Ilmiah Universitas Batanghari Jambi, 22(3), 1470-1472.

Riegg Cellini, S., & Edwin Kee, J. (2015). Cost‐effectiveness and cost‐benefit analysis. Handbook of practical program evaluation, 636-672.

Sanders, G. D., Maciejewski, M. L., & Basu, A. (2019). Overview of cost-effectiveness analysis. Jama, 321(14), 1400-1401.

Sica, D. A. (2005). Angiotensin‐Converting Enzyme Inhibitors' Side Effects—Physiologic and Non‐Physiologic Considerations. The Journal of Clinical Hypertension, 7, 17-23.

Staessen, J. A., Wang, J., Bianchi, G., & Birkenhäger, W. H. (2003). Essential hypertension. The Lancet, 361(9369), 1629-1641.

Weintraub, W. S., & Cohen, D. J. (2009). The limits of cost-effectiveness analysis. Circulation: Cardiovascular Quality and Outcomes, 2(1), 55-58.

Wu, J., Kraja, A. T., Oberman, A., Lewis, C. E., Ellison, R. C., Arnett, D. K., ... & Rao, D. C. (2005). A summary of the effects of antihypertensive medications on measured blood pressure. American Journal Of Hypertension, 18(7), 935-942.